Trial Profile
Phase II trial of doxorubicin and bortezomib in patients with incurable head and neck adenoid cystic carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2016
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Doxorubicin
- Indications Adenoid cystic carcinoma; Head and neck cancer
- Focus Therapeutic Use
- 01 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 08 Jun 2010 Study details were reported at ASCO 2010.